Cargando…

Comparing antigenaemia- and microfilaraemia as criteria for stopping decisions in lymphatic filariasis elimination programmes in Africa

BACKGROUND: Mass drug administration (MDA) is the main strategy towards lymphatic filariasis (LF) elimination. Progress is monitored by assessing microfilaraemia (Mf) or circulating filarial antigenaemia (CFA) prevalence, the latter being more practical for field surveys. The current criterion for s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stolk, Wilma A., Coffeng, Luc E., Bolay, Fatorma K., Eneanya, Obiora A., Fischer, Peter U., Hollingsworth, T. Déirdre, Koudou, Benjamin G., Méité, Aboulaye, Michael, Edwin, Prada, Joaquin M., Caja Rivera, Rocio M., Sharma, Swarnali, Touloupou, Panayiota, Weil, Gary J., de Vlas, Sake J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9779720/ https://www.ncbi.nlm.nih.gov/pubmed/36508458 http://dx.doi.org/10.1371/journal.pntd.0010953

Ejemplares similares

An investigation of the disparity in estimates of microfilaraemia and antigenaemia in lymphatic filariasis surveys
por: Cano, Jorge, et al.
Publicado: (2015)

Standardisation of lymphatic filariasis microfilaraemia prevalence estimates based on different diagnostic methods: a systematic review and meta-analysis
por: Vinkeles Melchers, Natalie V. S., et al.
Publicado: (2020)

Quantifying the value of surveillance data for improving model predictions of lymphatic filariasis elimination
por: Michael, Edwin, et al.
Publicado: (2018)

Delays in lymphatic filariasis elimination programmes due to COVID-19, and possible mitigation strategies
por: Prada, Joaquín M, et al.
Publicado: (2021)

Elimination or Resurgence: Modelling Lymphatic Filariasis After Reaching the 1% Microfilaremia Prevalence Threshold
por: Prada, Joaquin M, et al.
Publicado: (2020)

Are Alternative Strategies Required to Accelerate the Global Elimination of Lymphatic Filariasis? Insights From Mathematical Models
por: Stolk, Wilma A, et al.
Publicado: (2018)

Combining different diagnostic studies of lymphatic filariasis for risk mapping in Papua New Guinea: a predictive model from microfilaraemia and antigenaemia prevalence surveys
por: Berg Soto, Alvaro, et al.
Publicado: (2018)

Progress towards onchocerciasis elimination in Côte d’Ivoire: A geospatial modelling study
por: Eneanya, Obiora A., et al.
Publicado: (2021)

Advances and challenges in predicting the impact of lymphatic filariasis elimination programmes by mathematical modelling
por: Stolk, Wilma A, et al.
Publicado: (2006)

Modeling the Impact and Costs of Semiannual Mass Drug Administration for Accelerated Elimination of Lymphatic Filariasis
por: Stolk, Wilma A., et al.
Publicado: (2013)

Impact of Annual versus Semiannual Mass Drug Administration with Ivermectin and Albendazole on Helminth Infections in Southeastern Liberia
por: Eneanya, Obiora A., et al.
Publicado: (2022)

Statistical methods for linking geostatistical maps and transmission models: Application to lymphatic filariasis in East Africa
por: Touloupou, Panayiota, et al.
Publicado: (2022)

Understanding the relationship between prevalence of microfilariae and antigenaemia using a model of lymphatic filariasis infection
por: Irvine, Michael A., et al.
Publicado: (2016)

Geospatial modelling of lymphatic filariasis and malaria co-endemicity in Nigeria
por: Eneanya, Obiora A, et al.
Publicado: (2023)

Impact of annual and semi-annual mass drug administration for Lymphatic Filariasis and Onchocerciasis on Hookworm Infection in Côte d’Ivoire
por: Loukouri, Agodio, et al.
Publicado: (2020)

The effect of assortative mixing on stability of low helminth transmission levels and on the impact of mass drug administration: Model explorations for onchocerciasis
por: de Vos, Anneke S., et al.
Publicado: (2018)

The impact of mass drug administration expansion to low onchocerciasis prevalence settings in case of connected villages
por: de Vos, Anneke S., et al.
Publicado: (2021)

Efficacy and Safety of a Single Dose of Ivermectin, Diethylcarbamazine, and Albendazole for Treatment of Lymphatic Filariasis in Côte d’Ivoire: An Open-label Randomized Controlled Trial
por: Bjerum, Catherine M, et al.
Publicado: (2019)

Required duration of mass ivermectin treatment for onchocerciasis elimination in Africa: a comparative modelling analysis
por: Stolk, Wilma A., et al.
Publicado: (2015)

Environmental suitability for lymphatic filariasis in Nigeria
por: Eneanya, Obiora A., et al.
Publicado: (2018)

Canine microfilaraemia in some regions of Iran
por: Hosseini, Seyed Hossein, et al.
Publicado: (2022)

Temporal variability of Loa loa microfilaraemia
por: Campillo, Jérémy T., et al.
Publicado: (2023)

Low transmission of Wuchereria bancrofti in cross-border districts of Côte d’Ivoire: A great step towards lymphatic filariasis elimination in West Africa
por: Yokoly, Firmain N., et al.
Publicado: (2020)

Mapping the baseline prevalence of lymphatic filariasis across Nigeria
por: Eneanya, Obiora A., et al.
Publicado: (2019)

Elimination of African Onchocerciasis: Modeling the Impact of Increasing the Frequency of Ivermectin Mass Treatment
por: Coffeng, Luc E., et al.
Publicado: (2014)

Predictive Value of Ov16 Antibody Prevalence in Different Subpopulations for Elimination of African Onchocerciasis
por: Coffeng, Luc E, et al.
Publicado: (2019)

Community-based trial assessing the impact of annual versus semiannual mass drug administration with ivermectin plus albendazole and praziquantel on helminth infections in northwestern Liberia
por: Eneanya, Obiora A., et al.
Publicado: (2022)

Systems analysis-based assessment of post-treatment adverse events in lymphatic filariasis
por: Andersen, Britt J., et al.
Publicado: (2019)

Structural Uncertainty in Onchocerciasis Transmission Models Influences the Estimation of Elimination Thresholds and Selection of Age Groups for Seromonitoring
por: Hamley, Jonathan I D, et al.
Publicado: (2020)

Effectiveness of community-based burden estimation to achieve elimination of lymphatic filariasis: A comparative cross-sectional investigation in Côte d’Ivoire
por: Simpson, Hope, et al.
Publicado: (2022)

Modelling Anti-Ov16 IgG4 Antibody Prevalence as an Indicator for Evaluation and Decision Making in Onchocerciasis Elimination Programmes
por: Lont, Yvonne L., et al.
Publicado: (2017)

Achieving herd immunity against COVID-19 at the country level by the exit strategy of a phased lift of control
por: de Vlas, Sake J., et al.
Publicado: (2021)

How does onchocerciasis-related skin and eye disease in Africa depend on cumulative exposure to infection and mass treatment?
por: Vinkeles Melchers, Natalie V. S., et al.
Publicado: (2021)

No Evidence for Lymphatic Filariasis Transmission in Big Cities Affected by Conflict Related Rural-Urban Migration in Sierra Leone and Liberia
por: de Souza, Dziedzom K., et al.
Publicado: (2014)

Understanding the relationship between egg- and antigen-based diagnostics of Schistosoma mansoni infection pre- and post-treatment in Uganda
por: Prada, Joaquín M., et al.
Publicado: (2018)

Temporal epidemiology of microfilaraemia among migrant workers entering Kuwait
por: Akhtar, Saeed, et al.
Publicado: (2008)

Pharmacokinetics of Moxidectin combined with Albendazole or Albendazole plus Diethylcarbamazine for Bancroftian Filariasis
por: Chhonker, Yashpal S., et al.
Publicado: (2023)

African Program for Onchocerciasis Control 1995–2010: Impact of Annual Ivermectin Mass Treatment on Off-Target Infectious Diseases
por: Krotneva, Stanimira P., et al.
Publicado: (2015)

The burden of skin disease and eye disease due to onchocerciasis in countries formerly under the African Programme for Onchocerciasis Control mandate for 1990, 2020, and 2030
por: Vinkeles Melchers, Natalie V. S., et al.
Publicado: (2021)

Progress towards lymphatic filariasis elimination in Ghana from 2000-2016: Analysis of microfilaria prevalence data from 430 communities
por: Biritwum, Nana Kwadwo, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_9eo7d1722r8bani7pg8g94psac